WARNING: AVOID USE IN PREG NANCY
When pregnancy is detected, discontinue Tekturna HCT as soon as possible. D rugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. [ See Warnings and Precautions (5.1) ]
TEKTURNA HCT SUMMARY
Tekturna†HCT is a fixed combination of aliskiren, an orally active, nonpeptide, potent direct renin inhibitor, and hydrochlorothiazide, a thiazide diuretic.
Tekturna†HCT is indicated for the treatment of hypertension.
Both aliskiren and hydrochlorothiazide are associated with dose-dependent and dose-independent adverse effects. Patients treated with Tekturna†HCT may experience any or all of these adverse effects. For dose-dependent adverse effects, using a strength of Tekturna†HCT with a lower dose of the component suspected of causing the adverse effect may produce better tolerability.
A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna†HCT.
A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna†HCT.
A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna†HCT†containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions.
Tekturna†HCT may be substituted for the titrated components.
Limitation of Use
This fixed dose combination is not indicated for initial therapy.
Media Articles Related to Tekturna HCT (Aliskiren / Hydrochlorothiazide)
Calorie restriction improves sleep apnea, hypertension in obese people
Source: Hypertension News From Medical News Today [2014.09.12]
Restricting calories may improve obstructive sleep apnea and reduce high blood pressure in obese adults, according to a study presented at the American Heart Association's High Blood Pressure...
Hypertension up to Six Times More Likely in Obese vs Slim Youth
Source: theheart.org | Medscape Cardiology Headlines [2014.09.10]
Overweight and obese boys and girls were much more likely to have hypertension than normal-weight children in a new study; thus, weight loss should be encouraged to reduce later CVD risk.
Hypertension is a nearly 6 fold risk factor in obese youths
Source: Hypertension News From Medical News Today [2014.09.03]
Obese youths have a nearly six fold risk of hypertension, according to research in more than 22 000 young people from the PEP Family Heart Study presented at ESC Congress by Professor Peter Schwandt...
Stroke risk increased by resistant hypertension: 35 percent in women and 20 percent in elderly Taiwanese
Source: Hypertension News From Medical News Today [2014.09.03]
Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan.
Potential to treat pulmonary hypertension with protein in 'good cholesterol'
Source: Cholesterol News From Medical News Today [2014.09.01]
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis.
Published Studies Related to Tekturna HCT (Aliskiren / Hydrochlorothiazide)
Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. [2011.10.01]
BACKGROUND: Hypertension frequently coexists with diabetes mellitus, resulting in increased cardiovascular risk. Thus, BP control is crucial in decreasing morbidity and mortality in this difficult-to-treat patient population. OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of aliskiren in hypertensive patients with diabetes not adequately responsive to the combination of valsartan and hydrochlorothiazide (HCT)... CONCLUSION: The reductions in BP with aliskiren added to valsartan/HCT in this study were numerically greater compared with placebo added to valsartan/HCT, although not statistically significant. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00219102.
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. [2011.05]
Efficacy of antihypertensive agents on central blood pressure (BP) in African Americans is not well studied. The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy...
Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. [2011.03]
Patients with stage 2 systolic hypertension require sizable blood pressure (BP) reductions to achieve recommended targets. This randomized double-blind study compared a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (aliskiren/HCTZ) with HCTZ monotherapy in older patients (older than 55 years) with systolic BP >/=160 mm Hg and <200 mm Hg...
Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study. [2010.12]
Patients with stage 2 hypertension (systolic blood pressure [SBP] >/=160mm Hg and/or diastolic blood pressure [DBP] >/=100mm Hg) are at high cardiovascular risk and require intensive blood pressure (BP)-lowering therapy. This randomized double-blind study is the first prospective trial specifically designed to evaluate the direct renin inhibitor aliskiren in patients with a mean sitting SBP >/=160 mm Hg and <180mm Hg (the lower ranges of stage 2 systolic hypertension)...
Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. [2009.04]
OBJECTIVE: Thiazide diuretics such as hydrochlorothiazide (HCT) are a widely used first-line treatment for hypertension, but most patients will not achieve blood pressure (BP) control with HCT alone and so will require combination therapy. In this study the efficacy, safety and tolerability of a single-pill combination (SPC) of the direct renin inhibitor aliskiren with HCT were investigated in patients non-responsive to HCT 25 mg therapy... CONCLUSION: Aliskiren/HCT SPCs provide clinically significant BP reductions and improved BP control rates in patients who are non-responsive to HCT 25 mg monotherapy. Limitations of the study were the mainly Caucasian patient population and the non-responder design.
Clinical Trials Related to Tekturna HCT (Aliskiren / Hydrochlorothiazide)
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction [Recruiting]
The primary objective of this study is to determine whether treatment with aliskiren (300
mg) compared to placebo will improve treadmill exercise time in older (age ‚Č• 55 years)
patients with heart failure and normal ejection fraction (HFNEF).
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis [Recruiting]
We will study the hypothesis that long-term Tekturna treatment will improve endothelial
function and the production and function of endothelial progenitor cells (EPCs) in patients
with early atherosclerosis. Specifically, long-term Tekturna treatment will increase the
Reactive Hyperemia Peripheral Arterial Tonometry indexes and increase the numbers and the
function of circulating endothelial progenitor cells, compared to placebo, in association
with a reduction in inflammation and oxidative stress.
Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension [Recruiting]
In this research study, the goal is to find out if a currently FDA-approved medication
called Tekturna(Aliskiren) along with the addition of Vitamin D will lower blood pressure
and improve heart function in the African American population. High blood pressure occurs
earlier in life in African Americans, is more severe, and is associated with greater organ
damage in relation to uncontrolled hypertension. Having low levels of Vitamin D is also very
common in the African American population. Research has shown that there may be a link
between low Vitamin D levels and the ability of high blood pressure medications to be fully
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease [Recruiting]
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during
renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to
conventional ARB therapy (35-45% over 9 months). The investigators hypothesize that
aldosterone breakthrough occurs due to accumulation of active precursor substances, most
notably angiotensin II, produced in response to conventional RAAS blockade with
ACEinhibitors and ARBs. The investigators believe that direct renin inhibition (DRI) should
minimize this accumulation and therefore significantly lower or possibly eliminate the
Interruption of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting
enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), alone and in
combination, has become a leading therapy to slow the progression of chronic heart and
kidney disease. Both types of drugs inhibit the formation of aldosterone, a hormone, which
has been shown to have harmful effects on patients with chronic heart and kidney disorders.
This treatment is effective but not perfect since, even after an initial improvement, many
patients become worse over the long term. This may be due to an unexpected increase in
aldosterone, a phenomenon called "aldosterone breakthrough."
The purpose of this study is to find out whether the use of a direct renin inhibitor (DRI)
alone, or in combination with an angiotensin receptor blocker (ARB), will lessen the
occurrence of aldosterone breakthrough since direct renin inhibitors inhibit the formation
of aldosterone at a very early step. This study will compare the effectiveness of adding
Diovan (valsartan) or Tekturna (aliskiren) or a combination of Diovan and Tekturna to the
usual antihypertensive treatment. The investigators will follow blood pressure, aldosterone
levels, and urinary protein levels over 9 months to evaluate which of these therapies is
most effective for treating hypertension in patients with proteinuric kidney disease.
Comparison of Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries and Endothelial Dysfunction [Not yet recruiting]
This study will be performed only at the Jewish General Hospital. It will investigate the
effect of treatment with aliskiren, an inhibitor of renin, a substance produced by the
kidney that constricts arteries and raises blood pressure, on the blood vessels,
specifically the arteries, of subjects who have diabetes and elevated blood pressure
To investigate blood vessels, different techniques will be used. For large arteries, these
will be studied by non invasive methods using detection of the pulse wave or using
ultrasound over the skin of the neck, the wrist and the groin. To study small vessels, the
investigators will perform a biopsy on the buttock, under local anesthesia, and obtain a
small sample of tissue from under the skin, from which the vessels will be dissected. The
investigators have performed many hundreds of these small biopsies over the past 20 years
for similar studies without any complications. The biopsies are very well tolerated. From
this research the investigators will thus be able to learn what the structure and function
of these vessels is in these patients, in comparison to a normal healthy group.
The hypertensive diabetic subjects will then be assigned by chance (randomized trial) to
treatment with the renin inhibitor aliskiren or a comparator, the diuretic
hydrochlorothiazide. Aliskiren is a relatively new drug used to treat hypertension that is
very well tolerated and is now being evaluated in numerous trials in hypertensive diabetic
individuals. The diuretic is a well-know agent used to treat high blood pressure now for
many years, and which is very well tolerated. Physicians, nurses and scientists involved in
the study will be unaware of who is receiving which drug, as will be the patients (this is
the meaning of double-blind trial). However, if there is any problem, the secret code will
be broken and the individual withdrawn from the study. Subjects will be treated for a year,
and the study procedures (non invasive and the biopsy) repeated at 6 months and after one
year of treatment. During the study, blood samples will be drawn and urine collected at
certain intervals to ensure safety of the treatment.
Once tissues are obtained they will be studied in the laboratory. The study of the vessels
will allow treatment us to determine how the treatment with the renin inhibitor aliskiren
affects the structure and function as well as cellular and molecular aspects of arteries of
hypertensive diabetic persons. The investigators expect these studies to provide us
knowledge on mechanisms and perhaps new targets for future therapies of cardiovascular
disease and hypertension.
Reports of Suspected Tekturna HCT (Aliskiren / Hydrochlorothiazide) Side Effects
Feeling Abnormal (7),
Blood Pressure Increased (5),
Oedema Peripheral (4),
Diabetes Mellitus (3),
Drug Ineffective (3),
Blood Pressure Inadequately Controlled (3), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Tekturna HCT has an overall score of 1. The effectiveness score is 2 and the side effect score is 4. The scores are on ten point scale: 10 - best, 1 - worst.
Tekturna HCT review by 75 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || high blood pressure|
|Dosage & duration:|| || 300mg/12.5 mg taken 1 x daily for the period of 3 weeks |
|Other conditions:|| || dermatomyositis,hypothyroidism |
|Other drugs taken:|| || levothyroxine, prednisone|
|Benefits:|| || none,pressure never came down to acceptable range and had wide swings throughout the day|
|Side effects:|| || pounding headache, nausea, dizziness while walking and arising from bed/chair, spots in eye, uncontrollable eye tearing. The latter two are still present after6 weeks on not taking meds.|
|Comments:|| || they didn't work even after dossage was increased, Monitored at home and in doctor's office, results were the same.|
Page last updated: 2014-09-12